Inhaled Treatment of Respiratory Infections
Respiratory infections are conventionally treated with oral or intravenous antimicrobials (antivirals, antibiotics, and antifungals). However, these routes of administration are not ideal because the required drugs are systemically delivered rather than being targeted to the respiratory tract. Highe...
Saved in:
| 格式: | Online |
|---|---|
| 語言: | 英语 |
| 出版: |
MDPI - Multidisciplinary Digital Publishing Institute
2024
|
| 主題: | |
| 在線閱讀: | ONIX_20240514_9783725803927_182 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|
| _version_ | 1869514082128756736 |
|---|---|
| collection | Directory of Open Access Books |
| description | Respiratory infections are conventionally treated with oral or intravenous antimicrobials (antivirals, antibiotics, and antifungals). However, these routes of administration are not ideal because the required drugs are systemically delivered rather than being targeted to the respiratory tract. Higher doses may also be needed to achieve sufficient drug concentrations in the lungs, which may consequently increase the risk of adverse effects. On the other hand, the drugs can be efficiently delivered into the airways as inhaled aerosols. Lower doses can then be used to attain relatively high local concentrations. There are specific challenges to the development of inhaled formulations, such as the optimisation of their physicochemical stability and aerosol performance. In addition, antimicrobial resistance is an urgent global public health issue. Novel strategies are required to overcome these problems. The papers in this reprint focus on recent advancements in inhaled antimicrobials and vaccines, including those for viral (SARS‑CoV‑2), bacterial (Mycobacterium tuberculosis, Mycoplasma pneumoniae, Acinetobacter baumanii), and fungal infections (moulds). |
| format | Online |
| id | doab-20.500.12854ir-137582 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1375822024-05-14T13:37:48Z Inhaled Treatment of Respiratory Infections Kwok, Philip Chi Lip Chow, Michael phage therapy spray drying bacterial lung infections environmental humidity aerosol performance inhalation hydroxychloroquine coronavirus disease 2019 (COVID-19) vibrating mesh nebuliser aerosol droplet packing density product density small porous particles corrugated particles angiotensin-(1–7) Mycoplasma pneumoniae asthma inflammation macrophages capreomycin dry powder aerosol pulmonary delivery tuberculosis antifungal drugs invasive fungal disease animal model antifungal prophylaxis therapeutic antibody aggregates immunogenicity polymeric micelles Soluplus® rifampicin curcumin inhalable nanoformulation active drug targeting Mycobacterium tuberculosis dry powder inhaler immune regulation isoniazid mannose conjugation macrophage phenotype next-generation impactor nasal spray liquid film translocation supine position wall liquid-holding capacity nasopharynx mucosal immunization drug combination inhalable dry powders resistance development synergistic effect cyclosporine-A spray-drying SARS-CoV-2 cytokine storm transplant rejection ARDS COVID-19 C-ARDS plasminogen lung in vitro model immunomodulating activity thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology::MKGW Psychopharmacology Respiratory infections are conventionally treated with oral or intravenous antimicrobials (antivirals, antibiotics, and antifungals). However, these routes of administration are not ideal because the required drugs are systemically delivered rather than being targeted to the respiratory tract. Higher doses may also be needed to achieve sufficient drug concentrations in the lungs, which may consequently increase the risk of adverse effects. On the other hand, the drugs can be efficiently delivered into the airways as inhaled aerosols. Lower doses can then be used to attain relatively high local concentrations. There are specific challenges to the development of inhaled formulations, such as the optimisation of their physicochemical stability and aerosol performance. In addition, antimicrobial resistance is an urgent global public health issue. Novel strategies are required to overcome these problems. The papers in this reprint focus on recent advancements in inhaled antimicrobials and vaccines, including those for viral (SARS‑CoV‑2), bacterial (Mycobacterium tuberculosis, Mycoplasma pneumoniae, Acinetobacter baumanii), and fungal infections (moulds). 2024-05-14T13:37:37Z 2024-05-14T13:37:37Z 2024 book ONIX_20240514_9783725803927_182 9783725803927 9783725803910 https://directory.doabooks.org/handle/20.500.12854/137582 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/8767 https://mdpi.com/books/pdfview/book/8767 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-0391-0 10.3390/books978-3-7258-0391-0 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725803927 9783725803910 270 open access |
| spellingShingle | phage therapy spray drying bacterial lung infections environmental humidity aerosol performance inhalation hydroxychloroquine coronavirus disease 2019 (COVID-19) vibrating mesh nebuliser aerosol droplet packing density product density small porous particles corrugated particles angiotensin-(1–7) Mycoplasma pneumoniae asthma inflammation macrophages capreomycin dry powder aerosol pulmonary delivery tuberculosis antifungal drugs invasive fungal disease animal model antifungal prophylaxis therapeutic antibody aggregates immunogenicity polymeric micelles Soluplus® rifampicin curcumin inhalable nanoformulation active drug targeting Mycobacterium tuberculosis dry powder inhaler immune regulation isoniazid mannose conjugation macrophage phenotype next-generation impactor nasal spray liquid film translocation supine position wall liquid-holding capacity nasopharynx mucosal immunization drug combination inhalable dry powders resistance development synergistic effect cyclosporine-A spray-drying SARS-CoV-2 cytokine storm transplant rejection ARDS COVID-19 C-ARDS plasminogen lung in vitro model immunomodulating activity thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology::MKGW Psychopharmacology Inhaled Treatment of Respiratory Infections |
| title | Inhaled Treatment of Respiratory Infections |
| title_full | Inhaled Treatment of Respiratory Infections |
| title_fullStr | Inhaled Treatment of Respiratory Infections |
| title_full_unstemmed | Inhaled Treatment of Respiratory Infections |
| title_short | Inhaled Treatment of Respiratory Infections |
| title_sort | inhaled treatment of respiratory infections |
| topic | phage therapy spray drying bacterial lung infections environmental humidity aerosol performance inhalation hydroxychloroquine coronavirus disease 2019 (COVID-19) vibrating mesh nebuliser aerosol droplet packing density product density small porous particles corrugated particles angiotensin-(1–7) Mycoplasma pneumoniae asthma inflammation macrophages capreomycin dry powder aerosol pulmonary delivery tuberculosis antifungal drugs invasive fungal disease animal model antifungal prophylaxis therapeutic antibody aggregates immunogenicity polymeric micelles Soluplus® rifampicin curcumin inhalable nanoformulation active drug targeting Mycobacterium tuberculosis dry powder inhaler immune regulation isoniazid mannose conjugation macrophage phenotype next-generation impactor nasal spray liquid film translocation supine position wall liquid-holding capacity nasopharynx mucosal immunization drug combination inhalable dry powders resistance development synergistic effect cyclosporine-A spray-drying SARS-CoV-2 cytokine storm transplant rejection ARDS COVID-19 C-ARDS plasminogen lung in vitro model immunomodulating activity thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology::MKGW Psychopharmacology |
| topic_facet | phage therapy spray drying bacterial lung infections environmental humidity aerosol performance inhalation hydroxychloroquine coronavirus disease 2019 (COVID-19) vibrating mesh nebuliser aerosol droplet packing density product density small porous particles corrugated particles angiotensin-(1–7) Mycoplasma pneumoniae asthma inflammation macrophages capreomycin dry powder aerosol pulmonary delivery tuberculosis antifungal drugs invasive fungal disease animal model antifungal prophylaxis therapeutic antibody aggregates immunogenicity polymeric micelles Soluplus® rifampicin curcumin inhalable nanoformulation active drug targeting Mycobacterium tuberculosis dry powder inhaler immune regulation isoniazid mannose conjugation macrophage phenotype next-generation impactor nasal spray liquid film translocation supine position wall liquid-holding capacity nasopharynx mucosal immunization drug combination inhalable dry powders resistance development synergistic effect cyclosporine-A spray-drying SARS-CoV-2 cytokine storm transplant rejection ARDS COVID-19 C-ARDS plasminogen lung in vitro model immunomodulating activity thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology::MKGW Psychopharmacology |
| url | ONIX_20240514_9783725803927_182 |